Vol. 4 No. 4 (2024)
Reimbursement Reviews

Belumosudil (Rezurock)

decorative image of the issue cover

Published April 30, 2024

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses belumosudil (Rezurock), 200 mg oral tablets once daily.
  • Indication: For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy.